| Non-Small Cell Lung Carcinoma
Cyramza vs Xalkori
Side-by-side clinical, coverage, and cost comparison for non-small cell lung carcinoma.Deep comparison between: Cyramza vs Xalkori with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsXalkori has a higher rate of injection site reactions vs Cyramza based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Xalkori but not Cyramza, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Cyramza
Xalkori
At A Glance
IV infusion
Every 2 weeks
VEGFR2 antagonist
Oral
Twice daily
ALK/ROS1 inhibitor
Indications
- Gastric Adenocarcinoma
- Non-Small Cell Lung Carcinoma
- Metastasis from malignant neoplasm of colon and/or rectum
- Liver carcinoma
- Non-Small Cell Lung Carcinoma
- Ki-1+ Anaplastic Large Cell Lymphoma
- Inflammatory Myofibroblastic Tumor
Dosing
Gastric Adenocarcinoma 8 mg/kg every 2 weeks by IV infusion as a single agent or in combination with weekly paclitaxel.
Non-Small Cell Lung Carcinoma (EGFR exon 19/21, first-line) 10 mg/kg every 2 weeks by IV infusion in combination with erlotinib.
Non-Small Cell Lung Carcinoma (post-platinum progression) 10 mg/kg by IV infusion on Day 1 of a 21-day cycle in combination with docetaxel.
Metastasis from malignant neoplasm of colon and/or rectum 8 mg/kg every 2 weeks by IV infusion prior to FOLFIRI.
Liver carcinoma 8 mg/kg every 2 weeks by IV infusion as a single agent.
Non-Small Cell Lung Carcinoma Adults: 250 mg orally twice daily until disease progression or unacceptable toxicity.
Ki-1+ Anaplastic Large Cell Lymphoma Pediatric patients 1 year of age and older and young adults: 280 mg/m2 orally twice daily (BSA-based dosing) until disease progression or unacceptable toxicity.
Inflammatory Myofibroblastic Tumor Adults: 250 mg orally twice daily; pediatric patients 1 year of age and older: 280 mg/m2 orally twice daily (BSA-based dosing), until disease progression or unacceptable toxicity.
Contraindications
—
—
Adverse Reactions
Most common (>=10%) Hypertension, fatigue/asthenia, neutropenia, diarrhea, epistaxis, peripheral edema, stomatitis, proteinuria, thrombocytopenia, decreased appetite, nausea.
Serious Febrile neutropenia, pneumonia, hemorrhage, gastrointestinal perforation, arterial thromboembolic events, impaired wound healing, posterior reversible encephalopathy syndrome, proteinuria including nephrotic syndrome, infusion-related reactions, sepsis.
Postmarketing Thrombotic microangiopathy, hemangioma, dysphonia, arterial aneurysms/dissections/rupture, heart failure.
Most common (>=25%) Vision disorders, nausea, diarrhea, vomiting, edema, constipation, elevated transaminases, fatigue, decreased appetite, upper respiratory infection, dizziness, neuropathy.
Serious Hepatotoxicity, interstitial lung disease/pneumonitis, QT interval prolongation, bradycardia, severe visual loss, gastrointestinal toxicity (in pediatric/young adult ALCL or pediatric IMT patients).
Postmarketing Increased blood creatine phosphokinase.
Pharmacology
Ramucirumab is a VEGFR2 antagonist that specifically binds VEGFR2 and blocks binding of VEGFR ligands VEGF-A, VEGF-C, and VEGF-D, inhibiting ligand-stimulated activation of VEGFR2 and thereby inhibiting endothelial cell proliferation, migration, and angiogenesis.
Crizotinib is an inhibitor of receptor tyrosine kinases including ALK, ROS1, c-Met, and RON; it blocks ALK fusion protein-driven oncogenic signaling, inhibiting tumor cell proliferation and survival.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Cyramza
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (0/12) · Qty limit (0/12)
Xalkori
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (0/12) · Qty limit (11/12)
UnitedHealthcare
Cyramza
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Xalkori
- Covered on 4 commercial plans
- PA (2/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Cyramza
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (0/3)
Xalkori
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Cyramza.
Cost estimate not availableAssistance Fund: Non-Small Cell Lung Cancer (NSCLC)
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
CyramzaView full Cyramza profile
XalkoriView full Xalkori profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.